

Alphalyse A/S Roedegaardsvej 209C 5230 Odense M Denmark Alphalyse Inc 299 California Ave, Ste 200 Palo Alto, CA 94306 USA



HCP-ELISA characterization and coverage

Do your HCP-ELISAs cover all critical Host Cell Proteins?

Choose the best ELISA for your biologic

Traditionally, HCP-ELISA coverage has been evaluated by spot counting in 2D-PAGE and Western blotting, which is inaccurate and difficult to reproduce. The ELISA-MS[™] analysis uses immunocapture in the ELISA plate format and LC-MS for protein identification. It provides detailed and accurate information about each HCP in your process and product, plus the coverage % of your HCP-ELISA assay - reducing the risk of project delays due to problematic HCPs.



Compare ELISAs and document HCP coverage

Characterize coverage percentage, identify covered vs. uncovered HCPs, - including high-risk HCPs - and select the best fit ELISA for your product.

Bridging studies

Characterize changes in ELISA reagents or methods implemented during development and lead to inconsistent result.

Troubleshoot ELISAs

Investigate issues with antibody/drug substance cross-reactivity, insufficient specificity, incorrect standards for the calibration curve, etc.

Example of results

3 ELISA kits were used on an early process sample in which 1265 HCPs were identified by LC-MS. 952 of them were covered by ELISA A, 917 by ELISA B, and 662 by ELISA C, corresponding to coverages of 75%, 72%, 52%. The lists were compared to the top 10 HCPs identified by LC-MS in the purified drug substance. ELISA A showed the best coverage of the early process sample (75%) and the most abundant HCPs in the drug substance (9 of 10).



Specific coverage of HCPs in drug substance

	ELISA A	ELISA B	ELISA C
Oxidoreductase A	+	+	+
Protein B	+	+	-
C Reductase	+	+	+
Cyclohydrolase D	+	-	+
Regulation protein E	+	-	-
Heat shock protein F	+	+	-
Protein G	-	+	-
Dehydrogenase H	+	+	+
Protein I	+	+	+
Chaperone J	+	+	+
Specific coverage	9/10	8/10	6/10





LC-MS analysis

Principles of ELISA-MS[™]

The method is based on immunocapture using ELISA antibodies immobilized in a plate combined with LC-MS protein identification and quantification.

What customers say

"Using the Alphalyse ELLISA-MS[™] method for ELISA selection, we estimate savings of approximately \$1M and, likely, one year of development time."

SAVARA Aps, Denmark Lars Skriver - Senior Science Officer

Why work with us?

- 20+ years of experience helping biotech companies in Europe and USA
- 500+ MS-based HCP projects makes us the World's most experienced lab



Contact

info@alphalyse.com alphalyse.com/coverage (650) 543-3193

